Research programme: erythropoietin/albumin - Teva

Drug Profile

Research programme: erythropoietin/albumin - Teva

Alternative Names: Albumin/erythropoietin; Albupoietin; EPO/albumin; Long-acting EPO - Teva; Long-acting erythropoietin

Latest Information Update: 12 Aug 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CoGenesys
  • Developer Teva Pharmaceutical Industries
  • Class Erythropoietins
  • Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anaemia

Most Recent Events

  • 22 Feb 2008 CoGenesys has been acquired and merged into Teva Pharmaceutical Industries
  • 30 Aug 2006 This programme is available for licensing (http://www.cogenesys.com)
  • 12 Jun 2006 CoGenesys has acquired this programme from Human Genome Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top